ACTRN12616000294459已完成不适用
A Phase I, safety, tolerability and efficacy study of topical AKP-11 administration to participants with atopic dermatitis.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •*Males or females aged 18-65 years (inclusive) at the time of screening.
- •*Individuals diagnosed with atopic dermatitis according to the criteria of Hanifin and Rajka.
- •*Individuals with mild to moderate disease and equal to 10 % of BSA with atopic dermatitis.
- •*Participants with L-EASI score of equal to 1 for each of the signs at an appropriate target site.
- •*Able to provide written informed consent proper to the performance of any study specific procedures.
- •*Participants with a BMI between 18.0 and 40.0 kg/m2, inclusive.
- •*Female participants of child-bearing potential with negative pregnancy test at screening and negative urine pregnancy test at check-in (Day 1), AND;
- •*Agrees to abstinence for the duration of the study and until 4 weeks after dosing with study drug, if this is in line with the usual and preferred lifestyle;
- •*OR agrees to use condoms plus one other acceptable form of contraception; i.e. intra-uterine device, hormonal contraception (oral, injected or implanted) or a female diaphragm, from screening until 4 weeks after dosing with study drug;
- •*OR has only same-sex partners, when this is her preferred and usual lifestyle;
- •*OR has a vasectomized partner, which should be the sole partner for that participant.
- •*Male participants with female partners of child-bearing potential must agree abstinence or to use condoms plus partner use of an acceptable contraceptive (intrauterine device, hormonal contraception such as oral, injected or implanted; or male condom plus female diaphragm or cervical cap) for the duration of the study and until 4 weeks after dosing with study drug.
- •* Negative test results for Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C at the time of screening.
- •*Negative drug screening test (drugs of abuse; Creatinine control, testing for amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines) result (urine test) at the time of screening.
- •*Participants who are willing and able to comply with all study assessments and adhere to the protocol schedule.
排除标准
- •*Participants with any skin condition other than atopic dermatitis in particular cutaneous infections, significant sun damage or an inherited skin disorder that in the opinion of the Investigator could interfere with the evaluation of the trial medication.
- •*History of allergy and/ or hypersensitivity to any of the stated ingredients of the formulations.
- •*Participants who have smoked more than 10 cigarettes a day in the last 12 months.
- •*Treatment with any of the following within 4 weeks prior to the commencement of study treatment and for the duration of the study: systemic retinoids; immunosuppressant agents (e.g. methotrexate, cyclosporine, azathioprine, thioguanine prednisone, prednisolone, hydroxyurea or mycophenolate mofetil); phototherapy or photochemotherapy; high potency topical corticosteroids; alternative medicine” treatments; or sun exposure or tanning bed use, or any other therapy that in the opinion of the investigator could modify disease activity.
- •*Topical treatment within 2 weeks prior to commencement of study treatment and for the duration of the study, including: moderate potency topical corticosteroids; topical retinoids; or keratolytics, coal tar and dithranol or any other topical that in the opinion of the investigator could modify disease activity.
- •*Have received any investigational research agent or therapeutic biologic within 30 days or 5 half-lives (whichever is longer) prior to the first dose of Investigational Product.
- •*Have received an investigational vaccine within 6 months, a live attenuated vaccine within 60 days or a registered vaccine within 30 days prior to the first dose of the Investigational Product.
- •*Have evidence of drug or alcohol abuse within 6 months prior to screening visit (i.e., more than fourteen units of alcohol per week [1 Unit = 150 ml of wine 360 ml of beer, or 45 ml of 40% alcohol]).
- •*Have clinical signs of active infection and/or a temperature of above 38.0 degrees of C at the time of screening. Study entry may be deferred at the discretion of the Principal Investigator.
- •*Anticipate surgery within the trial period or history of major surgery within 3 months of screening.
- •*A depot injection or an implant of any drug within 3 months prior to administration of study treatment, with the exception of a contraceptive implant.
- •*Participants who are unable to sign consent or unable to return for all scheduled study visits.
- •*Evidence of current or previous clinically significant neurological, endocrinal, cardiovascular, pulmonary, haematological, malignant, immunologic, psychiatric metabolic or other uncontrolled systemic disease, or finding of the medical examination (including vital signs and ECG), including any other condition that in the opinion of the investigator, would compromise the safety of the participant or interfere with assessment of endpoints or unsuitable for enrollment or impact on the quality of the data.
研究者
相似试验
尚未招募
1 期
Combination therapy of iPS-NKT cell and DC/GalJPRN-jRCTa030220741Iinuma Tomohisa6
进行中（未招募）
1 期
Gene therapy study with autologous hemapoietic stem cells for patients affected by MPSIHEUCTR2017-002430-23-ITOSPEDALE SAN RAFFAELE6
进行中（未招募）
1 期
Gene therapy study with autologous hemapoietic stem cells for patients affected by MPSIHMucopolysaccharidosis type I HurlerCTIS2024-514870-29-00Ospedale San Raffaele S.r.l.8
进行中（未招募）
1 期
Studio di terapia genica con cellule staminali ematopoietiche autologheEUCTR2014-004860-39-ITOSPEDALE SAN RAFFAELE10
已完成
1 期
Phase 1 study to evaluate the safety and efficacy of jyuzentaihoto in infantile anal fistulainfantile anal fistulaJPRN-UMIN000021336Kanazawa University20